Novavax (NASDAQ:NVAX) announces positive results from a Phase 3 clinical trial comparing quadrivalent influenza vaccine candidate NanoFlu to Sanofi’s (NASDAQ:SNY) Fluzone Quadrivalent.
The study met the primary endpoints of safety and non-inferior immunogenicity.
All key secondary endpoints were met or exceeded.
The company intends to bring Fast Track-tagged NanoFlu to market as soon as possible.
Management will host a conference call this morning at 8:30 am ET to discuss the results.
https://seekingalpha.com/news/3554554-novavax-up-29-premarket-on-successful-nanoflu-study
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.